POS0622 THE BLOOD T-CELL SUBSETS IN RHEUMATOID ARTHRITIS PATIENTS ON LONG-TERM IL-6 RECEPTOR BLOCKER THERAPY
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.2310
Abstract: Pleiotropic effects of IL-6 receptor antagonist tocilizumab (TCZ) in rheumatoid arthritis (RA) involve circulating T-cells. Preliminary reports have suggested that TCZ therapy can modulate T cell function and humoral immune responses in RA [1,2]. According… read more here.
Keywords: cells cd3; therapy; cell; rheumatoid arthritis ... See more keywords
Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Antibiotics"
DOI: 10.3390/antibiotics11020241
Abstract: (1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterized by the release of several immune modulators, including Interleukin-6 (IL-6). Tocilizumab (TCZ) is an IL-6 receptor antagonist used to treat rheumatic arthritis. The… read more here.
Keywords: covid patients; tcz therapy; retrospective study; covid ... See more keywords